<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03930212</url>
  </required_header>
  <id_info>
    <org_study_id>Prog133077</org_study_id>
    <nct_id>NCT03930212</nct_id>
  </id_info>
  <brief_title>Progesterone Supplementation in Threatened Abortion</brief_title>
  <acronym>Prothreat</acronym>
  <official_title>Progesterone Supplementation in Threatened Abortion: Is it a Sound Practice?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To decide whether progesterone supplementation in threatened abortion is a sound practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was conducted at Obstetrics and Gynecology Department, Tanta University in the
      period from January 2018 to December 2018. Patients: Eligible patients (n=190) were randomly
      allocated into 2 groups; study group who will receive progesterone supplementation
      (Prog.group) and control group who will receive no treatment (place.group).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relief of pain</measure>
    <time_frame>3 weeks</time_frame>
    <description>questionnaire fulfilled by patient with yes or no questions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>completion of pregnancy beyond 20 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>passing the age 20 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stoppage of bleeding</measure>
    <time_frame>3 weeks</time_frame>
    <description>Cessation of bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>abortion less than 20 weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Abortion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Threatened Abortion</condition>
  <condition>Progesterone Resistance</condition>
  <arm_group>
    <arm_group_label>Progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received rectal progesterone suppositories 400 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received placebo suppositories rectally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>received rectal progesterone suppositories 400 mg once daily</description>
    <arm_group_label>Progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>received placebo suppositories rectally once daily.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  threatened abortion diagnosed by history and ultrasound examination

          -  singleton

          -  viable fetus

          -  gestational age &lt; 20 weeks

          -  closed normal length cervix.

        Exclusion Criteria:

          -  short cervix &lt;2 cm Multiple pregnancy

          -  dead fetus

          -  open cervix â‰¥ 2cm

          -  history of cervical surgery

          -  refusal to participate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ayman Shehata Dawood</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Ayman S Dawood, MD</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Threatened</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>2 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

